Lisata Therapeutics Inc (LSTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.65+0.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LSTA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 0.2 | 0.2 | 0.0 | 0.0 | — | — | — | — | — | 35.3 | 22.5 | 17.9 | 14.7 | 14.3 | 10.1 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | 35.3 | 22.5 | 17.9 | 14.7 | 14.3 | 10.1 |
| Cost of Revenues | — | — | — | — | — | — | — | — | — | — | 31.1 | 20.2 | 15.7 | 12.9 | 11.9 | 8.6 |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.7 | 2.4 | 1.4 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | — | — | — | 13.0 | 14.1 | 11.5 | 9.9 | 9.3 | 9.4 | 11.8 | 12.8 | 30.0 | 30.8 | 21.6 | 22.3 | 27.7 |
| R&D Expenses | — | — | — | — | — | 17.7 | 9.3 | 10.8 | 7.6 | 15.8 | 16.7 | 23.9 | 29.2 | 16.9 | 10.5 | 7.7 |
| Other Operating Expenses, Total | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (0.6) | (0.6) |
| Operating Income | (16.4) | (18.2) | (18.2) | (25.7) | (57.6) | (29.1) | (19.1) | (20.1) | (17.0) | (27.6) | (29.5) | (113.8) | (57.7) | (36.8) | (30.4) | (34.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.4 | 1.8 | 2.1 | 0.8 | 0.3 | 1.6 | 2.6 |
| Other Non-Operating Income / Expenses | 1.4 | 0.7 | 0.7 | 2.5 | 0.9 | 0.1 | 0.1 | 0.7 | 0.8 | (0.1) | (1.8) | 15.6 | 2.2 | (1.9) | (5.9) | (0.6) |
| EBT, Incl. Unusual Items | (15.0) | (17.5) | (17.5) | (23.2) | (56.7) | (29.0) | (19.0) | (19.4) | (16.2) | (27.7) | (31.3) | (98.3) | (55.6) | (38.7) | (36.3) | (56.2) |
| Income Tax Expense | — | (1.0) | (1.0) | (2.3) | (2.5) | (1.5) | (10.9) | 0.0 | 0.0 | (11.5) | 0.0 | (17.2) | (0.1) | 0.8 | (0.2) | 0.0 |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | (16.2) | (16.2) | — | — | (55.5) | (39.5) | (36.1) | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (9.4) |
| Net Income | (14.6) | (16.6) | (16.6) | (20.8) | (54.2) | (27.5) | (8.2) | (19.4) | (16.2) | 23.0 | (33.3) | (81.0) | (54.9) | (39.0) | (53.8) | (47.1) |
| Per Share | ||||||||||||||||
| Basic EPS | (1.61) | (1.91) | (1.91) | (2.58) | (10.47) | (7.45) | (0.53) | — | (1.67) | 2.56 | — | — | — | — | — | — |
| Diluted EPS | (1.61) | (1.91) | (1.91) | (2.58) | (10.47) | (7.45) | (0.53) | — | — | 2.56 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 9.1 | 8.7 | 8.7 | 8.1 | 5.2 | 3.7 | 15.4 | — | 9.7 | 9.0 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 9.1 | 8.7 | 8.7 | 8.1 | 5.2 | 3.7 | 15.4 | — | 9.7 | 9.0 | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (18.1) | (18.1) | (25.5) | (57.5) | (29.0) | (19.1) | (20.0) | (16.8) | (27.2) | (29.1) | (111.2) | (55.6) | (35.2) | (28.8) | (32.6) |
| EBIT | (16.4) | (18.2) | (18.2) | (25.7) | (57.6) | (29.1) | (19.1) | (20.1) | (17.0) | (27.6) | (29.5) | (113.8) | (57.7) | (36.8) | (30.4) | (34.0) |
| Effective Tax Rate | — | 5.5% | — | 10.1% | 4.4% | 5.2% | 57.2% | 0.0% | 0.0% | 41.6% | 0.0% | 17.5% | 0.2% | -2.0% | 0.5% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.